Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARCT-2304

Vaccine (mRNA vaccine) · Immune activation · developed by Arcturus Therapeutics

Phase 1/2 Most advanced trial (none active)

ARCT Developer

1 Registered trials

What is ARCT-2304?

ARCT-2304 is a self-amplifying mRNA vaccine against pandemic influenza, given as a two-dose intramuscular regimen into the deltoid muscle. It is studied for the prevention of influenza in humans.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (mRNA vaccine)
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: Arcturus Therapeutics, Inc. (ARCT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06602531	Phase 1/2	Influenza, Human	Completed	ARCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Influenza, Human

More from Arcturus Therapeutics

ARCT-021 Phase 2 ARCT-032 Phase 2 ARCT-154 Phase 2/3 ARCT-165 Phase 1/2 ARCT-2138 Phase 1 ARCT-2303 Phase 3 ARCT-810 Phase 2

Sources

ClinicalTrials.gov NCT06602531

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARCT page.

Follow ARCT, the company behind ARCT-2304

See ARCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARCT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z